MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)

S. Gray, M. Lewis, T. Kazdoba, A. Koenig, E. Lefler, K. Paumier, M. Quirk, J. Doherty (Cambridge, USA)

Meeting: 2023 International Congress

Abstract Number: 883

Keywords: Cognitive dysfunction, NMDA, Pharmacotherapy

Category: Huntington's Disease

Objective: To investigate correlations between plasma levels of 24(S)-Hydroxycholesterol (24[S]-HC) and cognitive performance in participants with Huntington’s disease (HD) using data from ENROLL-HD.

Background: HD is characterized by progressive motor, psychiatric, and cognitive symptoms. Evidence suggests that dysregulated cholesterol metabolism contributes to HD pathogenesis. In the brain, 24(S)-HC is the main cholesterol metabolite and is a potent endogenous positive allosteric modulator (PAM) of N-methyl-D-aspartate receptors (NMDARs). Reduced plasma and brain levels of 24(S)-HC have been observed in all HD stages. In our prior analysis of TRACK-HD study data, correlations between plasma 24(S)-HC levels and cognitive performance were examined in participants with premanifest HD and early HD, and healthy controls (n=60 per group). Results showed that plasma 24(S)-HC levels were reduced in early HD and positively correlated with performance on cognitive measures. These findings were not solely driven by neurodegenerative processes (ie, cell loss) and were specific to 24(S)-HC [1].

Method: We sought to replicate these findings by conducting a separate analysis of the larger ENROLL-HD data set, expanding our analysis to examine the ratios of 24(S)-HC to 25-HC and 27-HC (other metabolites).

Results: In ENROLL-HD, plasma 24(S)-HC levels were significantly reduced in patients with manifest HD (n=149) vs premanifest HD (n=123). 24(S)/25-HC and 24(S)/27-HC ratios were lower in patients with manifest HD vs premanifest HD and controls (n=121). Among participants with HD and premanifest HD, 24(S) ratios were negatively correlated with CAG-Age-Product score. Across all participants, 24(S)-HC (but not 25- or 27-HC) as well as 24(S) ratios were positively correlated with cognitive performance.

Conclusion: These findings align with the prior TRACK-HD analysis and suggest that NMDAR hypofunction due to lower 24(S)-HC and 24(S) ratios may contribute to cognitive impairment in HD. In an effort to understand the potential therapeutic benefit of modulating NMDARs, SAGE-718, a novel NMDAR PAM, is currently under investigation for the potential treatment of cognitive impairment due to HD and other neurodegenerative diseases.

References: 1. Lewis M, et al. Presented at: American Academy of Neurology Annual Meeting; May 4–10, 2019. Philadelphia, Pennsylvania, USA.

To cite this abstract in AMA style:

S. Gray, M. Lewis, T. Kazdoba, A. Koenig, E. Lefler, K. Paumier, M. Quirk, J. Doherty. 24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD) [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/24s-hydroxycholesterol-and-cognition-in-huntingtons-disease-results-from-two-large-patient-cohorts-track-hd-and-enroll-hd/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/24s-hydroxycholesterol-and-cognition-in-huntingtons-disease-results-from-two-large-patient-cohorts-track-hd-and-enroll-hd/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley